Apyx Medical Corp. (APYX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook
May 8, 2019 4:05 PM EDTAdvanced Energy Sales of $4.4 million in Q1, up 66% year-over-year
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March31, 2019.
First Quarter 2019 Financial Summary:
Total Q1 revenue from continuing operations of $5.8 million, up 71% year-over-year. Advanced Energy revenue of $4.4 million, up 66% year-over-year.... More


